Evidence map›Paper›PMID 32632839›Full record

ArticleEndocrine pathology2020

Stem Cell Transcription Factor Sox2 Is Expressed in a Subset of Folliculo-stellate Cells of Growth Hormone-Producing Pituitary Neuroendocrine Tumours and Its Expression Shows No Association with Tumour Size or IGF1 Levels: a Clinicopathological Study of 109 Cases.

Jiri Soukup, Tomáš Česák, Helena Hornychová, Květoslava Michalová, Ľudmila Michnová, David Netuka, Jan Čáp, Filip Gabalec

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jiri SoukupThe Fingerland Department of Pathology, University Hospital and Faculty of Medicine Hradec Kralove, Charles University, Sokolska 581, 500 05, Hradec Kralove, Czech Republic. 2jiri.soukup@gmail.com.ORCID https://orcid.org/0000-0001-7169-4386
Tomáš ČesákDepartment of Neurosurgery, University Hospital and Faculty of Medicine Hradec Kralove, Charles University, Sokolska 581, 500 05, Hradec Kralove, Czech Republic.
Helena HornychováThe Fingerland Department of Pathology, University Hospital and Faculty of Medicine Hradec Kralove, Charles University, Sokolska 581, 500 05, Hradec Kralove, Czech Republic.
Květoslava MichalováDepartment of Pathology, Faculty of Medicine in Plzen, Charles University, Plzen, Czech Republic.
Ľudmila MichnováDepartment of Pathology, Military University Hospital Prague, Prague, Czech Republic.
David NetukaDepartment of Neurosurgery and Neurooncology, 1st Medical Faculty, Charles University, Military University Hospital Prague, Prague, Czech Republic.
Jan Čáp4th Department of Internal Medicine, University Hospital and Faculty of Medicine Hradec Kralove, Charles University, Sokolska 581, 500 05, Hradec Kralove, Czech Republic.
Filip Gabalec4th Department of Internal Medicine, University Hospital and Faculty of Medicine Hradec Kralove, Charles University, Sokolska 581, 500 05, Hradec Kralove, Czech Republic.
Charles University · CZMilitary University Hospital Prague · CZ

Funding

Ministerstvo Zdravotnictví Ceské Republiky NV19-01-00435
6 · The paper itself

Abstract

Sox2 is one of the transcription factors responsible for the maintenance of stem cell phenotype. It has been implicated as a marker of stem cells in normal pituitaries and pituitary neuroendocrine tumours. To explore the clinical significance of Sox2 expression in histological sections, we performed immunohistochemical detection of Sox2 in 113 pituitary neuroendocrine tumours from 109 patients with acromegaly. In 11 tumours, we performed double immunostaining for Sox2, annexin A1 and S100 protein. Tumours were characterised using the WHO classification system. Proliferative activity and invasion were assessed. The amount of immunoreactive cells was evaluated and correlated with tumour size and biochemical features (levels of IGF1, GH, prolactin, βTSH). Sox2

Indexed as

AcromegalyAdultBiomarkers, TumorFemaleHuman Growth HormoneHumansInsulin-Like Growth Factor IMaleMiddle AgedNeuroendocrine TumorsPituitary NeoplasmsSOXB1 Transcription FactorsStem CellsBiomarkers, TumorHuman Growth HormoneIGF1 protein, humanInsulin-Like Growth Factor ISOX2 protein, humanSOXB1 Transcription FactorsAcromegalyPitNETPituitary neuroendocrine tumoursSox2Stem cells

Identifiers

PMID32632839
OpenAlexW3038973942

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.